1. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
- Author
-
Yamile, Zabana, Ignacio, Marín-Jiménez, Iago, Rodríguez-Lago, Isabel, Vera, María Dolores, Martín-Arranz, Iván, Guerra, Javier, P Gisbert, Francisco, Mesonero, Olga, Benítez, Carlos, Taxonera, Ángel, Ponferrada-Díaz, Marta, Piqueras, Alfredo, J Lucendo, Berta, Caballol, Míriam, Mañosa, Pilar, Martínez-Montiel, Maia, Bosca-Watts, Jordi, Gordillo, Luis, Bujanda, Noemí, Manceñido, Teresa, Martínez-Pérez, Alicia, López, Cristina, Rodríguez-Gutiérrez, Santiago, García-López, Pablo, Vega, Montserrat, Rivero, Luigi, Melcarne, María, Calvo, Marisa, Iborra, Manuel, Barreiro de Acosta, Beatriz, Sicilia, Jesús, Barrio, José Lázaro, Pérez Calle, David, Busquets, Isabel, Pérez-Martínez, Mercè, Navarro-Llavat, Vicent, Hernández, Federico, Argüelles-Arias, Fernando, Ramírez Esteso, Susana, Meijide, Laura, Ramos, Fernando, Gomollón, Fernando, Muñoz, Gerard, Suris, Jone, Ortiz de Zarate, José María, Huguet, Jordina, Llaó, Mariana Fe, García-Sepulcre, Mónica, Sierra, Miguel, Durà, Sandra, Estrecha, Ana, Fuentes Coronel, Esther, Hinojosa, Lorenzo, Olivan, Eva, Iglesias, Ana, Gutiérrez, Pilar, Varela, Núria, Rull, Pau, Gilabert, Alejandro, Hernández-Camba, Alicia, Brotons, Daniel, Ginard, Eva, Sesé, Daniel, Carpio, Montserrat, Aceituno, José Luis, Cabriada, Yago, González-Lama, Laura, Jiménez, María, Chaparro, Antonio, López-San Román, Cristina, Alba, Rocío, Plaza-Santos, Raquel, Mena, Sonsoles, Tamarit-Sebastián, Elena, Ricart, Margalida, Calafat, Sonsoles, Olivares, Pablo, Navarro, Federico, Bertoletti, Horacio, Alonso-Galán, Ramón, Pajares, Pablo, Olcina, Pamela, Manzano, Eugeni, Domènech, Maria, Esteve, On Behalf Of The Eneida Registry Of Geteccu, Universidad de Sevilla. Departamento de Medicina, Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, and Consorci Sanitari de Terrassa
- Subjects
COVID-19 ,SARS-CoV-2 ,inflammatory bowel disease ,5-aminosalicylates ,immunosuppression ,Immunosupressió ,Factors de risc en les malalties ,Risk factors in diseases ,terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunosupresión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,General Medicine ,Inflammatory bowel diseases ,COVID-19 (Malaltia) ,enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES] ,Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Inflammatory bowel disease ,Malalties inflamatòries intestinals ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES] ,Intestins - Inflamació ,Immunosuppression - Abstract
COVID-19; Immunosuppression; Inflammatory bowel disease COVID-19; Immunosupressió; Malaltia inflamatòria intestinal COVID-19; Inmunosupresión; Enfermedad inflamatoria intestinal (1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case−control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March−July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3−5.9), occupational risk (OR: 2.9; 95%CI: 1.8−4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2−2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09−0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.
- Published
- 2022